Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Eastman Board Declares Dividend (Business Wire) +++ EASTMAN CHEMICAL Aktie -3,17%

BRISTOL-MYERS Aktie

 >BRISTOL-MYERS Aktienkurs 
47.745 EUR    -0.8%    (TradegateBSX)
Ask: 48.03 EUR / 1250 Stück
Bid: 47.835 EUR / 1300 Stück
Tagesumsatz: 5029 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>BRISTOL-MYERS Performance
1 Woche: -7,6%
1 Monat: -4,0%
3 Monate: -8,4%
6 Monate: +18,0%
1 Jahr: +13,6%
laufendes Jahr: +3,6%
>BRISTOL-MYERS Aktie
Name:  BRISTOL-MYERS SQUIBBDL-10
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US1101221083 / 850501
Symbol/ Ticker:  BRM (Frankfurt) / BMY (NYSE)
Kürzel:  FRA:BRM, ETR:BRM, BRM:GR, NYSE:BMY
Index:  S&P500
Webseite:  https://www.bms.com/
Profil:  Bristol-Myers Squibb Company is a global biopharmaceutical firm founded in 1887 that discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines worldwide. Its portfolio addresses critical therapeutic areas inclu..
>Volltext..
Marktkapitalisierung:  98991.29 Mio. EUR
Unternehmenswert:  129982.34 Mio. EUR
Umsatz:  41267.95 Mio. EUR
EBITDA:  16217.94 Mio. EUR
Nettogewinn:  6192.49 Mio. EUR
Gewinn je Aktie:  3.04 EUR
Schulden:  39520.43 Mio. EUR
Liquide Mittel:  8149.4 Mio. EUR
Operativer Cashflow:  11326.09 Mio. EUR
Bargeldquote:  0.55
Umsatzwachstum:  -4.7%
Gewinnwachstum:  25.71%
Dividende je Aktie:  2.15 EUR
Dividendenrendite:  4.39%
Dividendenschätzung:  4.4%
Div. Historie:  02.04.26 - 0.546777€
02.01.26 - 0.5355€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  BRISTOL-MYERS, BRISTOL MYERS
Letzte Datenerhebung:  07.05.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 2042.07 Mio. St.
Frei handelbar: 99.74%
Rückkaufquote: -
Mitarbeiter: 32500
Umsatz/Mitarb.: 1.26 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 12.76%
Bewertung:
KGV: 15.66
KGV lG: 8.95
KUV: 2.4
KBV: 5.68
PEG-Ratio: 0.47
EV/EBITDA: 8.01
Rentabilität:
Bruttomarge: 66.07%
Gewinnmarge: 15.01%
Operative Marge: 31.67%
Managementeffizenz:
Gesamtkaprendite: 8.13%
Eigenkaprendite: 38.84%
 >Anleihen 
>Peer Group
Gesundheit, Neurologie/ psychische Behandlung/ Schlaganfälle, Onkologie/ Krebs- Behandlung, Herz-Kreislauf- Behandlung/ Kardiologie
 
08.05.26 - 00:03
The Agencies Building Pharma′s Next Decade Just Picked Their Software: Daily Command Launches With 18 of the Industry′s Most Senior Agency Leaders Already Inside It (PR Newswire)
 
Sanofi, Merck, Bristol Myers Squibb, Eli Lilly, Avalere Health, Deerfield, Havas Media, Omnicom Health Group, Real Chemistry, EVERSANA, Klick Health, Ogilvy Health and others among the firms whose senior leaders co-built Doceree's Daily Command. The product redefines how agencies plan,......
07.05.26 - 23:18
75 of Pharma′s Most Senior Marketers Just Walked Away From a $12 Billion Tool Stack (PR Newswire)
 
In a coordinated public declaration at the Doceree Makers Summit, brand and commercial leaders from Sanofi, Merck, Bristol Myers Squibb, Eli Lilly, Avalere Health, Deerfield, and others co-signed a new operating model for pharma marketing — and named the product replacing what they've......
07.05.26 - 22:03
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights (Business Wire)
 
JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate JANX011 Phase 1 study ongoing in healthy volunteers Discontinued development of JANX008 following completion of Phase 1a Achieved development candidate nomination under Bristol Myers Squibb collaboration, triggering milestone payment Strong cash position supporting continued pipeline execution SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended March 31, 2026, and provided a business update. "Our commitment to advancing a prostate cancer franchise is demonstrated by our continued progress with JANX007, clinical initiation of JANX014, and advancement of JANX013 toward the clinic,” said David Campbell, Ph.D., President and C...
06.05.26 - 11:06
American Factories Lag in Adopting A.I. This Drugmaker Is an Exception. (New York Times)
 
A Bristol Myers Squibb plant that makes cancer drugs was the only manufacturer in the U.S. recognized for innovation by the World Economic Forum this year....
30.04.26 - 22:48
Why Bristol Myers Squibb Stock Rocked the Market Today (Fool)
 
It scored crushing beats on both revenue and profitability in its first quarter....
30.04.26 - 21:57
Bristol-Myers signals 30% R&D cycle-time reduction while tracking toward upper end of 2026 guidance ranges (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.04.26 - 19:00
Bristol Myers (BMY) Q1 2026 Earnings Transcript (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
30.04.26 - 17:45
BMY′s Q1 Earnings Top Estimates, Breyanzi, Camzyos Drive Sales (Zacks)
 
Bristol-Myers beats Q1 estimates as strong Growth Portfolio sales and Eliquis demand offset legacy drug declines....
30.04.26 - 14:03
Bristol-Myers Squibb in charts: Q1 revenue from Eliquis, Yervoy, and Orencia rises Y/Y; Sprycel, Opdivo, and Pomalyst/Imnovid falls (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.04.26 - 13:54
ROUNDUP: Bristol-Myers Squibb Reaffirms FY26 Outlook (AFX)
 
NEW YORK CITY (dpa-AFX) - While reporting financial results for the first quarter on Thursday, Bristol-Myers Squibb Co. (BMY) reaffirmed its adjusted earnings and revenue growth guidance for the f......
30.04.26 - 13:48
Bristol Myers Squibb Co. Reports Rise In Q1 Bottom Line (AFX)
 
NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb Co. (BMY) reported earnings for its first quarter that Increases, from last yearThe company's bottom line came in at $2.677 billion, or $1.31 per sha......
30.04.26 - 13:45
Bristol-Myers posts Q1 beat thanks to growth portfolio (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
30.04.26 - 13:24
Bristol-Myers Squibb trumps Q1 estimates, maintains full-year outlook (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
30.04.26 - 13:06
Bristol Tops Estimates on New Drugs Ahead of Key Trial Results (Bloomberg)
 
Bristol Myers Squibb Co.'s quarterly profit and sales beat Wall Street's expectations, a sign of strength in the drugmaker's business as it awaits the results of closely watched clinical trials that will determine its future....
30.04.26 - 13:06
Bristol-Myers Squibb Company Non-GAAP EPS of $1.58 beats by $0.16, revenue of $11.5B beats by $580M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
29.04.26 - 16:33
Bristol-Myers Squibb Q1 Preview: Growth portfolio′s performance in focus (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
29.04.26 - 15:54
Do Wall Street Analysts Like Bristol-Myers Squibb Stock? (Barchart)
 
Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...
27.04.26 - 16:45
Exploring Analyst Estimates for Bristol Myers (BMY) Q1 Earnings, Beyond Revenue and EPS (Zacks)
 
Get a deeper insight into the potential performance of Bristol Myers (BMY) for the quarter ended March 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics....
27.04.26 - 12:36
Is Bristol Myers Squibb the Best Bargain in Big Pharma? (Fool)
 
This pharma stock is cheap for a reason....
26.04.26 - 22:12
Bristol Myers Squibb: Low Volatility Meets High Dividend Yield (Fool)
 
Volatility and dividend yield are important metrics for investors thinking about a long-term buy....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: In alten Schlössern spucken die Geister am liebsten. - Sprichwort Deutschland
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!